↓ Skip to main content

Ipilimumab administration for advanced melanoma in patients with pre-existing Hepatitis B or C infection: a multicenter, retrospective case series

Overview of attention for article published in Journal for Immunotherapy of Cancer, October 2014
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (80th percentile)

Mentioned by

twitter
9 tweeters

Citations

dimensions_citation
45 Dimensions

Readers on

mendeley
55 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Ipilimumab administration for advanced melanoma in patients with pre-existing Hepatitis B or C infection: a multicenter, retrospective case series
Published in
Journal for Immunotherapy of Cancer, October 2014
DOI 10.1186/s40425-014-0033-1
Pubmed ID
Authors

Sowmya Ravi, Kristen Spencer, Mary Ruisi, Nageatte Ibrahim, Jason J Luke, John A Thompson, Keisuke Shirai, David Lawson, Heddy Bartell, Ragini Kudchadkar, Ngoc Thi Gunter, Janice M Mehnert, Evan J Lipson

Abstract

Ipilimumab is a fully human, monoclonal antibody directed against Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) that has demonstrated a survival benefit and durable disease control in patients with advanced melanoma. Ipilimumab is associated with potentially serious immune-related adverse events, including autoimmune hepatitis. Because clinical trials of ipilimumab excluded patients with pre-existing hepatitis B or C infection, there is a paucity of data on the safety of ipilimumab administration to that patient population. Here, we report the largest case series to date of patients with hepatitis B or C who received ipilimumab for advanced melanoma. Two of the nine patients described in this case series experienced fluctuations in their liver function tests (LFTs) and were subsequently treated with corticosteroids. Although this is a small series, the rate of hepatotoxicity appears similar to what has been seen in the general population treated with ipilimumab, and the ability to administer ipilimumab did not appear to be affected by concomitant hepatitis B or C infection. The use of ipilimumab in patients with metastatic melanoma who have pre-existing hepatitis can be considered among other therapeutic options.

Twitter Demographics

The data shown below were collected from the profiles of 9 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 55 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
France 1 2%
Unknown 54 98%

Demographic breakdown

Readers by professional status Count As %
Other 9 16%
Researcher 8 15%
Student > Master 7 13%
Student > Ph. D. Student 5 9%
Student > Doctoral Student 3 5%
Other 9 16%
Unknown 14 25%
Readers by discipline Count As %
Medicine and Dentistry 21 38%
Agricultural and Biological Sciences 4 7%
Pharmacology, Toxicology and Pharmaceutical Science 3 5%
Biochemistry, Genetics and Molecular Biology 2 4%
Economics, Econometrics and Finance 2 4%
Other 4 7%
Unknown 19 35%

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 December 2017.
All research outputs
#2,727,307
of 12,487,608 outputs
Outputs from Journal for Immunotherapy of Cancer
#238
of 612 outputs
Outputs of similar age
#42,306
of 213,718 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#1
of 3 outputs
Altmetric has tracked 12,487,608 research outputs across all sources so far. Compared to these this one has done well and is in the 78th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 612 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 19.8. This one has gotten more attention than average, scoring higher than 60% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 213,718 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 80% of its contemporaries.
We're also able to compare this research output to 3 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them